Themis Medicare Limited has informed the Exchange about change in Management- Appointment of Senior Management Personnel
THEMISMED · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Themis Medicare's Board met on August 1, 2025 and approved multiple items. Q1 FY26 standalone revenue stood at ₹9,757.77 lakhs, down about 21% year-on-year, with the company reporting a net loss of ₹1,537.37 lakhs versus a profit of ₹1,871.47 lakhs in the same quarter last year; EPS was ₹(1.67) vs ₹2.03. The Board appointed Ms. Neha Thakore as an Additional Non-Executive Woman Independent Director for 5 years and Mr. Viraj Save as Executive President – Sales & Marketing as a Senior Management Personnel. The Board also withdrew the previously announced merger scheme with Gujarat Themis Biosyn Limited after GTBL decided to focus on its core fermentation business, and approved the strike-off of its UK wholly-owned subsidiary Carpo Medicals Limited, writing off ₹128.63 lakhs in receivables as an exceptional item. The record date for the final dividend was fixed at September 5, 2025.
Shareholders should note the sharp swing into losses and the 21% revenue decline in Q1 FY26, along with the write-off linked to the UK subsidiary and the abandoned GTBL merger, which removes a previously expected strategic consolidation. The new leadership additions and confirmed final dividend provide some offset, but near-term earnings pressure is the key takeaway.